Michael J Pontecorvo
Overview
Explore the profile of Michael J Pontecorvo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
4751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abel A, Chambers A, Fill J, Reiske H, Lu M, Morris A, et al.
J Appl Lab Med
. 2025 Jan;
PMID: 39836199
Background: Blood-based biomarkers, especially P-tau217, have been gaining interest as diagnostic tools to measure Alzheimer disease (AD) pathology. Methods: We developed a plasma P-tau217 chemiluminescent immunoassay using 4G10E2 and IBA493...
2.
Rathore S, Higgins I, Wang J, Kennedy I, Iaccarino L, Burnham S, et al.
Alzheimers Dement (N Y)
. 2025 Jan;
10(4):e70005.
PMID: 39748844
Introduction: Alzheimer's disease is partially characterized by the progressive accumulation of aggregated tau-containing neurofibrillary tangles. Although the association between accumulated tau, neurodegeneration, and cognitive decline is critical for disease understanding...
3.
Freiburghaus T, Pawlik D, Oliveira Hauer K, Ossenkoppele R, Strandberg O, Leuzy A, et al.
Acta Neuropathol
. 2024 Sep;
148(1):44.
PMID: 39297933
[F]Flortaucipir is an FDA-approved tau-PET tracer that is increasingly utilized in clinical settings for the diagnosis of Alzheimer's disease. Still, a large-scale comparison of the in vivo PET uptake to...
4.
Leuzy A, Raket L, Villemagne V, Klein G, Tonietto M, Olafson E, et al.
Alzheimers Dement
. 2024 Jul;
20(9):5833-5848.
PMID: 39041435
Introduction: Tau-positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer...
5.
Niimi Y, Janelidze S, Sato K, Tomita N, Tsukamoto T, Kato T, et al.
Alzheimers Res Ther
. 2024 May;
16(1):115.
PMID: 38778353
Background: Maximizing the efficiency to screen amyloid-positive individuals in asymptomatic and non-demented aged population using blood-based biomarkers is essential for future success of clinical trials in the early stage of...
6.
Burnham S, Iaccarino L, Pontecorvo M, Fleisher A, Lu M, Collins E, et al.
Brain Commun
. 2024 Jan;
6(1):fcad305.
PMID: 38187878
Alzheimer's disease is defined by the presence of β-amyloid plaques and neurofibrillary tau tangles potentially preceding clinical symptoms by many years. Previously only detectable post-mortem, these pathological hallmarks are now...
7.
Zheng L, Rubinski A, Denecke J, Luan Y, Smith R, Strandberg O, et al.
Ann Neurol
. 2023 Oct;
95(2):274-287.
PMID: 37837382
Objective: We aimed to test whether region-specific factors, including spatial expression patterns of the tau-encoding gene MAPT and regional levels of amyloid positron emission tomography (PET), enhance connectivity-based modeling of...
8.
Costoya-Sanchez A, Moscoso A, Silva-Rodriguez J, Pontecorvo M, Devous Sr M, Aguiar P, et al.
JAMA Neurol
. 2023 Aug;
80(10):1051-1061.
PMID: 37578787
Importance: An increased tau positron emission tomography (PET) signal in the medial temporal lobe (MTL) has been observed in older individuals in the absence of amyloid-β (Aβ) pathology. Little is...
9.
Leuzy A, Binette A, Vogel J, Klein G, Borroni E, Tonietto M, et al.
JAMA Neurol
. 2023 May;
80(6):614-623.
PMID: 37155176
Importance: Longitudinal tau positron emission tomography (PET) is a relevant outcome in clinical trials evaluating disease-modifying therapies in Alzheimer disease (AD). A key unanswered question is whether the use of...
10.
Chen C, McCullough A, Gordon B, Joseph-Mathurin N, Flores S, McKay N, et al.
Eur J Nucl Med Mol Imaging
. 2023 Apr;
50(9):2669-2682.
PMID: 37017737
Purpose: Pittsburgh Compound-B (C-PiB) and F-florbetapir are amyloid-β (Aβ) positron emission tomography (PET) radiotracers that have been used as endpoints in Alzheimer's disease (AD) clinical trials to evaluate the efficacy...